[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovarian-endometrioid-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovarian-endometrioid-carcinoma":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100551922","ov-precision-study-examining-the-benefit-of-a-tumor--and-patient-specific-cancer-therapy-100551922",false,"NCT06466382","OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy","OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.","OVPrecision","Inclusion Criteria:\n\n* Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV\n* No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis\n* Envisaged surgical candidate for interval debulking after 2 cycles of treatment\n* Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures\n* ECOG 0-2\n* Written informed consent according to national legal and regulatory requirements prior to any project specific procedures\n\nExclusion Criteria:\n\n* Elevated liver enzymes (double of normal range: ASAT \\> 68 U\u002Fl; ALAT \\> 82 U\u002Fl; GGT \\> 80 U\u002Fl)\n* Elevated creatinine (double of normal range: \\>120 mmol\u002Fl))\n* ECOG ≥3\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has an impact on the prognosis of the patient\n* Inability to swallow tablets\n* Concurrent participation in another clinical trial on the same indication\n* Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance","FEMALE","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.",[27,28,29,30],"Ovarian Neoplasm Epithelial","Fallopian Tube Neoplasms","Ovarian Endometrioid Carcinoma","High-grade Serous Ovarian Carcinoma (HGSOC)",[32,33,34,35,36,37,38,39],"Primary ovarian cancer (OC)","Treatment naiive","Multi-modal tumor profiling","Treatment recommendation process","Multi-disciplinary tumor board","Patient benefit","Quality of Life (QoL)","Patient-personalized therapy","RECRUITING","2026-05-04",{"date":43,"type":44},"2026-05-05","ACTUAL",{"date":46,"type":44},"2025-03-31",{"date":48,"type":21},"2028-09",{"name":50,"class":51},"Swiss GO Trial Group","NETWORK",7,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100371101","phase-3-maintenance-therapy-with-aromatase-inhibitor-in-epithelial-ovarian-cancer-matao-100371101","NCT04111978","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)","MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54\u002FSwiss-GO-2\u002FMATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).","MATAO","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age\n* Willing and able to attend the visits and to understand all study-related procedures.\n* Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian\u002Ffallopian tube\u002Fperitoneal cancer\n* (Interval-) debulking performed ECOG-Performance Status 0-2\n* Signed informed consents (ICF-1; ICF-2)\n* Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available\n* Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)\n* At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)\n* Negative serum pregnancy test in women of childbearing potential who will get\u002Fhave gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.\n\nExclusion Criteria:\n\n* Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol\n* Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)\n* Pregnant or lactating women\n* Any other malignancy within the last 5 years which has impact on the prognosis of the patient\n* \\\u003C 4 cycles of chemotherapy in total\n* Contraindications to endocrine therapy\n* Inability or unwillingness to swallow tablets\n* Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption",{"count":62,"type":21},540,[64],"PHASE3","The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.\n\nThe study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).",[27,28,67,30,68,29],"Peritoneal Neoplasms","Low-grade Serous Ovarian Carcinoma (LGSOC)",[70,71,72,73],"maintenance therapy","aromatase inhibitor","primary ovarian cancer","estrogen-receptor","2025-09-23",{"date":76,"type":44},"2025-09-29",{"date":78,"type":44},"2020-11-05",{"date":80,"type":21},"2032-07-01",{"name":50,"class":51},53]